|
1. Biologie
|
|
|
|
2.3 Etiologie - OGM
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
Glyphosate And Cancer [In the Pipeline]
|
|
|
|
|
|
You
will hear that “MIT researchers” have “proven” that glyphosate does X
and Y and Z, and that this work is “published in peer-reviewed
journals”, but nothing like that is true.
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
3.6 Prévention - Activité physique
|
|
|
|
Well: Exercise Tied to Lower Risk for 13 Types of Cancer [NY Times]
|
|
|
|
|
|
Bear
in mind, though, that this was an observational study, so it cannot
directly prove that exercise reduces cancer risks, only that there is an
association between more exercise and less disease. It also relied on
participants’ memories of exercise, which can be unreliable.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2 Pharma
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
F.D.A. Approves an Immunotherapy Drug for Bladder Cancer [NY Times]
|
|
|
|
|
|
How
much of an impact immunotherapy will have on bladder cancer is a bit
unclear since patients have not been followed for a long time. But the
F.D.A. found Roche’s data compelling enough, and the need urgent enough,
to approve Tecentriq about four months ahead of the agency’s Sept. 12
deadline.
|
|
|
|
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.5.1.2 ASCO (général) - Académiques
|
|
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
Stem Cell Transplant Remains Important for Multiple Myeloma, Even in Novel Agent Era [ASCO]
|
|
|
|
|
|
Early
findings from a phase III clinical trial showed that patients with
multiple myeloma who received an autologous stem cell transplant (ASCT)
survived longer without disease progression than those who received only
chemotherapy using novel agents. This is the largest study reported to
date aimed at comparing ASCT with a bortezomib-based regimen alone in
patients younger than 65.
|
|
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
5.5.4 ASCO (immunothérapies)
|
|
|
|
5.5.5 ASCO (gastro-intestinal)
|
|
|
Side where colon cancer begins affects survival, finds study [STAT]
|
|
|
|
|
|
Presentations
at ASCO are not vetted as thoroughly as papers published in a
peer-reviewed journal, and typically much less data are available for
experts to assess. Nevertheless, physicians not associated with the
study said its findings seemed sound and made sense biologically.
|
|
|
|
|
|
|
|
Colon cancers 'more deadly on right' [BBC News]
|
|
|
|
|
|
Data
on more than 1,000 patients, released ahead of the world's biggest
cancer conference, showed a 14-month gulf in survival rates. Doctors
said location was probably a marker for a fundamentally different type
of tumour.
|
|
|
|
|
|
|
5.5.6 ASCO (peau-mélanome)
|
|
|
|
|
Skin cancer: Drug gives '40% melanoma survival' [BBC News]
|
|
|
|
|
|
Dr
Caroline Robert, a researcher at the Gustave Roussy Institute in
France, said: "Before 2011 advanced melanoma had a median overall
survival of less than one year and things have changed a lot. "What is
really exciting is to see at three years the estimated survival rate is
40% and this is regardless of previous treatment."
|
|
|
|
|
|
|
|
|
5.5.8 ASCO (poumon)
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10 Politiques
|
|
|
|